Nexalin Technology, Inc. announced on November 1, 2024, that it received notice from The Nasdaq Stock Market on October 31, 2024, confirming its regained compliance with Nasdaq’s minimum bid price requirement. This fulfills Nasdaq Rule 5550(a)(2), resolving a previous listing concern.
CEO Mark White stated that regaining compliance is a significant milestone for the company. It underscores Nexalin's commitment to driving shareholder value and strengthens its visibility among investors.
This achievement is important as Nexalin continues to advance its clinical research and pursue global regulatory approvals for its non-invasive neurostimulation treatments for mental health and neurological disorders.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.